Haptoglobin Expression Linked to Newborn Outcomes
By LabMedica International staff writers Posted on 09 Apr 2019 |

Image: Human IL-6 Luminex Performance ELISA Assay (Photo courtesy of R&D Systems).
Proteomics has facilitated discovery of biomarkers to better understand the pathophysiology of early-onset neonatal sepsis with the goal of identifying as early as possible the newborns more likely to die or develop significant morbidity.
Some preterm babies born without haptoglobin (Hp), a protein in blood cells, have higher odds of brain bleeding, cerebral palsy and death. This finding suggests that the absence of the protein could serve as a potential biomarker indicating a need for increased monitoring or other preventive interventions.
A large team of scientists working with the University of Illinois at Chicago (Chicago, IL, USA) evaluated cord blood samples from 921 newborns of women at imminent risk for preterm delivery randomized to either placebo (n = 471, birth gestational age (GA) median [min-max]: 31 [24–41] weeks) or magnesium sulphate (n = 450, GA 31 [24–42] weeks]). Primary outcome was infant death by 1 year and/or cerebral palsy (CP) ≥ 2 years of corrected age. Adjusted odd ratios (aOR) for neonatal and childhood outcomes were calculated controlling for GA, birth weight, sex, and magnesium exposure.
The team measured cord blood Hp and interleukin-6 (IL-6) concentrations in all samples. IL-6 was measured with commercial ELISA assays of low and high sensitivity. A cut-off in cord blood Hp immunoreactivity of 3,370 ng/mL in an enzyme-linked immunosorbent assay (ELISA) assay had ~ 100% sensitivity and specificity to segregate samples with switch-off from those with switch-on pattern on Western blots. Because the limit of detection for clinical assays to detect anhaptoglobinemia in adults is 2 mg/dL, Western blots were performed on all cord blood samples measuring Hp ≥ 2,000 ng/mL by ELISA (n = 507). Analysis of the magnesium concentration in cord serum was performed with a minimum detectable magnesium concentration of 0.4 mEq/L.
The scientists reported that primary outcome occurred in 2.8% of offspring. Newborns were classified in three pre-defined categorization groups by cord blood Hp switch status and IL-6 levels: inflammation-nonexposed (n = 432, 47%); inflammation-exposed haptoglobinemic (n = 449, 49%), and inflammation-exposed anhaptoglobinemic or hypohaptoglobinemic (n = 40, 4%). Newborns, found anhaptoglobinemic or hypohaptoglobinemic had increased OR for intraventricular hemorrhage (IVH) and/or death (aOR: 7.0) and for CP and/or death (aOR: 6.27) compared with Category 2. Fetal ability to respond to inflammation by haptoglobinemia resulted in aOR similar to inflammation-nonexposed newborns. Hp1-2 or Hp2-2 phenotypes protected against retinopathy of prematurity (aOR = 0.66).
The authors concluded that fetal ability to switch-on Hp expression in response to inflammation was associated with reduction of IVH and/or death, and CP and/or death. Fetuses unable to mount such a response had an increased risk of adverse outcomes. Catalin S. Buhimschi MD, a professor of obstetrics and gynecology the lead author of the study said, “Our study provides strong evidence that an absence of haptoglobin in preterm babies who have been exposed to inflammation is an indicator of increased risk for complications like brain bleeding, cerebral palsy and even death. This underscores the potential protective role of haptoglobin against short- and long-term poor neonatal outcomes and suggests that the protein may be a valuable marker of neurologic damage and the need for clinical interventions.” The study was published on March 22, 2019, in the journal EClinicalMedicine.
Related Links:
University of Illinois at Chicago
Some preterm babies born without haptoglobin (Hp), a protein in blood cells, have higher odds of brain bleeding, cerebral palsy and death. This finding suggests that the absence of the protein could serve as a potential biomarker indicating a need for increased monitoring or other preventive interventions.
A large team of scientists working with the University of Illinois at Chicago (Chicago, IL, USA) evaluated cord blood samples from 921 newborns of women at imminent risk for preterm delivery randomized to either placebo (n = 471, birth gestational age (GA) median [min-max]: 31 [24–41] weeks) or magnesium sulphate (n = 450, GA 31 [24–42] weeks]). Primary outcome was infant death by 1 year and/or cerebral palsy (CP) ≥ 2 years of corrected age. Adjusted odd ratios (aOR) for neonatal and childhood outcomes were calculated controlling for GA, birth weight, sex, and magnesium exposure.
The team measured cord blood Hp and interleukin-6 (IL-6) concentrations in all samples. IL-6 was measured with commercial ELISA assays of low and high sensitivity. A cut-off in cord blood Hp immunoreactivity of 3,370 ng/mL in an enzyme-linked immunosorbent assay (ELISA) assay had ~ 100% sensitivity and specificity to segregate samples with switch-off from those with switch-on pattern on Western blots. Because the limit of detection for clinical assays to detect anhaptoglobinemia in adults is 2 mg/dL, Western blots were performed on all cord blood samples measuring Hp ≥ 2,000 ng/mL by ELISA (n = 507). Analysis of the magnesium concentration in cord serum was performed with a minimum detectable magnesium concentration of 0.4 mEq/L.
The scientists reported that primary outcome occurred in 2.8% of offspring. Newborns were classified in three pre-defined categorization groups by cord blood Hp switch status and IL-6 levels: inflammation-nonexposed (n = 432, 47%); inflammation-exposed haptoglobinemic (n = 449, 49%), and inflammation-exposed anhaptoglobinemic or hypohaptoglobinemic (n = 40, 4%). Newborns, found anhaptoglobinemic or hypohaptoglobinemic had increased OR for intraventricular hemorrhage (IVH) and/or death (aOR: 7.0) and for CP and/or death (aOR: 6.27) compared with Category 2. Fetal ability to respond to inflammation by haptoglobinemia resulted in aOR similar to inflammation-nonexposed newborns. Hp1-2 or Hp2-2 phenotypes protected against retinopathy of prematurity (aOR = 0.66).
The authors concluded that fetal ability to switch-on Hp expression in response to inflammation was associated with reduction of IVH and/or death, and CP and/or death. Fetuses unable to mount such a response had an increased risk of adverse outcomes. Catalin S. Buhimschi MD, a professor of obstetrics and gynecology the lead author of the study said, “Our study provides strong evidence that an absence of haptoglobin in preterm babies who have been exposed to inflammation is an indicator of increased risk for complications like brain bleeding, cerebral palsy and even death. This underscores the potential protective role of haptoglobin against short- and long-term poor neonatal outcomes and suggests that the protein may be a valuable marker of neurologic damage and the need for clinical interventions.” The study was published on March 22, 2019, in the journal EClinicalMedicine.
Related Links:
University of Illinois at Chicago
Latest Immunology News
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
- Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients
- Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more